PLIANT THERAPEUTICS INC
For the period ended Dec 31, 2023. Filed Feb 27, 2024.
View on SEC.govAbout this filing
A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.
FY2023 · Filed Feb 27, 2024
PLRX$0.80-1.2%Stored close · as of Nov 9, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Statements of Cash Flows
(In thousands)
| Year Ended December 31, | |||
|---|---|---|---|
| 2023 | 2022 | 2021 | |
| Cash flows from operating activities | |||
| Net loss | $(161,336) | $(123,321) | $(97,263) |
| Adjustments to reconcile net loss to net cash used in operating activities: | |||
| Depreciation expense | 1,841 | 1,823 | 1,535 |
| Stock-based compensation expense | 44,483 | 22,598 | 10,437 |
| Non-cash operating lease expense | 2,390 | 1,858 | 1,669 |
| (Accretion) amortization on short-term investments and debt | (4,990) | (1,806) | 1,262 |
| Changes in operating assets and liabilities: | |||
| Accounts receivable | 1,983 | 15 | 7,281 |
| Prepaid expenses and other current assets | (3,735) | (294) | (2,266) |
| Other non-current assets | — | 201 | 70 |
| Accounts payable | 2,969 | (1,351) | 891 |
| Accrued liabilities | 2,781 | 7,904 | 2,695 |
| Operating lease liabilities | (2,747) | (2,258) | (1,754) |
| Net cash used in operating activities | (116,361) | (94,631) | (75,443) |
| Cash flows from investing activities | |||
| Purchase of short-term investments | (583,069) | (325,716) | (219,887) |
| Maturity of short-term investments | 456,978 | 177,272 | 295,539 |
| Purchase of property and equipment | (921) | (1,760) | (1,953) |
| Net cash (used in) provided by investing activities | (127,012) | (150,204) | 73,699 |
| Cash flows from financing activities | |||
| Proceeds from sale of common stock in a public offering | 270,251 | 216,201 | — |
| Proceeds from issuances of common stock under benefit plans | 5,001 | 1,360 | 2,984 |
| Payment of offering costs | (847) | (557) | (457) |
| Payment of debt issuance costs | — | (150) | — |
| Proceeds from term loan | — | 10,000 | — |
| Net cash provided by financing activities | 274,405 | 226,854 | 2,527 |
| Net increase (decrease) in cash and cash equivalents | 31,032 | (17,981) | 783 |
| Cash and cash equivalents at beginning of period | 33,684 | 51,665 | 50,882 |
| Cash, cash equivalents and restricted cash at end of period | $64,716 | $33,684 | $51,665 |
| Supplemental disclosures of cash flow information: | |||
| Cash paid for interest | $1,149 | $615 | $— |
| Reconciliation of cash, cash equivalents, and restricted cash reported in the balance sheets | |||
| Cash and cash equivalents | $63,234 | $33,684 | $51,665 |
| Restricted cash | 1,482 | — | — |
| Total cash, cash equivalents, and restricted cash shown in the statements of cash flows | $64,716 | $33,684 | $51,665 |
| Supplemental disclosures of noncash investing and financing activities: | |||
| Net unrealized gain(loss) on short-term investments | $2,303 | $(1,757) | $(169) |
| Purchase of property and equipment in accounts payable | $— | $— | $57 |
| Reclassification of restricted stock awards from liabilities to common stock upon vesting | $— | $2 | $9 |
| Supplemental disclosures of cash flow information related to leases: | |||
| Cash paid for operating lease liabilities in operating cash flows | $3,846 | $2,657 | $2,400 |
| Right-of-use assets obtained in exchange for new operating lease liabilities | $— | $950 | $— |
| Decrease in right-of -use assets and liabilities from lease modifications | $1,821 | $— | $— |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.